From Molecule to Market: Accelerating Oral Delivery of Peptides through Integrated Global Pharma Solutions and Advanced Enteric Technologies

As the pharmaceutical industry advances toward more targeted and patient-centric therapies, demand is growing for oral delivery technologies that can protect sensitive molecules from gastric conditions and support reliable intestinal release.

This session will explore how advanced enteric capsule technologies and integrated development services can help accelerate the oral delivery of acid-sensitive APIs, including small molecules, peptides, and live biotherapeutic products.

Lonza Capsugel's Enprotect® capsule offers a bi-layered, ready-to-use enteric solution designed to protect sensitive ingredients without the need for additional coating steps or complex downstream unit operations. When combined with Innovaform® Accelerator, formulation strategies can be tailored to molecule-specific requirements, supporting compatibility, performance, and optimized release profiles.

The session will also highlight how Lonza Capsugel’s broader Global Pharmaceutical Solutions offering supports oral solid dosage development from early concept through clinical and commercial manufacturing. By integrating formulation development, capsule technology, and cGMP manufacturing capabilities, Lonza Capsugel enables a more streamlined pathway from molecule to market for next generation oral therapies.